Access the full text.
Sign up today, get DeepDyve free for 14 days.
C Trodello, JP Pepper, M Wong, A Wysong (2017)
Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: a systematic review, 43
DJ Wong, A Ribas (2016)
Targeted therapy for melanoma, 167
PT Nghiem, S Bhatia, EJ Lipson (2016)
PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma, 374
GS Falchook, R Leidner, E Stankevich (2016)
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810, 4
MR Migden, A Guminski, R Gutzmer (2015)
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial, 16
R Asmar, J Yang, RD Carvajal (2016)
Clinical utility of nivolumab in the treatment of advanced melanoma, 12
H Johnson-Jahangir, D Ratner (2011)
Advances in management of dermatofibrosarcoma protuberans, 29
KL Harms, L Lazo de la Vega, DH Hovelson
Molecular profiling of multiple primary Merkel cell carcinoma to distinguish genetically distinct tumors from clonally related metastases
CK Bichakjian, T Olencki, M Alam (2014)
Merkel cell carcinoma, version 1.2014, 12
A Sekulic, MR Migden, AE Oro (2012)
Efficacy and safety of vismodegib in advanced basal-cell carcinoma, 366
HL Kaufman, J Russell, O Hamid (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial, 17
Opinion EDITORIAL Use of Targeted Therapy in the Treatment of Advanced Cutaneous Cancers M. Laurin Council, MD Now is an exciting time in the field of cutaneous oncology. More gins, whenever possible, is recommended. In addition, senti- nel lymph node biopsy is recommended in all cases where advances in the treatment of metastatic melanoma, ad- vanced basal and squamous cell carcinomas, and Merkel cell nodes are not clinically or radiologically enlarged. Postopera- carcinoma have been made in the past 5 years than in the pre- tive adjuvant irradiation is used to decrease recurrence rates. vious 5 decades. As in other Patients with positive sentinel lymph nodes, or nodes that are fields of oncology, the discov- clinically or radiologically suspect, undergo additional lymph Related article page 505 ery of targeted therapies has node dissection and irradiation and are enrolled in clinical trials revolutionized our treat- where offered. This is why the distinction between a primary ment of patients with advanced disease. Older cytotoxic agents Merkel cell carcinoma and a cutaneous metastasis is so criti- with substantial morbidity have been replaced with thera- cal. A second primary tumor should be treated with a wide ex- pies directed at specific aberrant pathways
JAMA Dermatology – American Medical Association
Published: Jun 12, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.